Jim Cramer Says Amgen (AMGN)'s New Drug Has Good Data
Cramer has recently started to discuss pharmaceutical giant Amgen Inc. (NASDAQ:AMGN) more frequently.
Amgen Inc (AMGN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 1,311,400 | $370,077,080 | -6% | 0.06% | |
| 2. | 957,900 | $270,319,380 | +1% | 0.04% | |
| 3. | Fisher Asset Management Ken Fisher | 785,284 | $221,607,369 | +92% | 0.08% |
| 4. | GLG Partners Noam Gottesman | 287,414 | $81,108,231 | +26% | 0.14% |
| 5. | 277,900 | $78,423,380 | +16% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.50 | 10 | $1,655.00 | 3,582 | 2015-08-19 | Filing | |
| $166.64 | 3,000 | $499,907.10 | 3,572 | 2015-08-19 | Filing | |
| $152.29 | 1,500 | $228,435.00 | 2,000 | 2015-02-05 | Filing | |
| $152.29 | 1,500 | $228,435.00 | 2,000 | 2015-02-05 | Filing | |
| $111.77 | 894 | $99,919.25 | 185,013 | 2014-05-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $337.26 | 1,639 | $552,773.24 | 7,225 | 2025-11-20 | Filing | |
| $337.26 | 1,500 | $505,893.75 | 7,225 | 2025-11-20 | Filing | |
| $336.24 | 890 | $299,255.56 | 7,082 | 2025-11-12 | Filing | |
| $336.83 | 6,879 | $2,317,071.46 | 41,923 | 2025-11-12 | Filing | |
| $296.99 | 1,267 | $376,280.00 | 7,209 | 2025-08-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 53,876,851 | $15,204,047,353 | 0.23% | |
| 2. | 46,034,432 | $12,990,916,763 | 0.23% | |
| 3. | 29,304,093 | $8,269,615,045 | 0.29% | |
| 4. | 19,192,995 | $5,414,295,672 | 0.87% | |
| 5. | 18,795,474 | $5,303,577,510 | 0.72% |
News See All
8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer continued his hard-hitting discussions of quantum computing.
Jim Cramer’s Latest Comments on These 17 Stocks
“It's starting to dawn on people: a market that only goes higher because of data center spending is a perilous market, and we don’t like that.
Jim Cramer Recently Put These 18 Stocks Under a Microscope
“Look out, the year of magical investing may be drawing to a close. All this year, pretty much anybody who bought stocks connected to AI and the data center, well, you know, you made money.
Amgen's (AMGN) Cholesterol Drug Is Very Important, Says JIm Cramer
Amgen Inc. (NASDAQ:AMGN) is a drug company that makes and sells medicines for a wide variety of ailments, such as arthritis and ulcers.
Jim Cramer Offered Insights on These 16 Stocks
“So it was the government shutdown and some insane comments from OpenAI about a government backstop because of gigantic spending that caused the sell-off.
12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing
In his latest appearance on CNBC's Squawk on the Street, Jim Cramer discussed quantum computing stocks and consumer spending.
Jim Cramer’s Recent Thoughts on These 8 Stocks
“This morning, when the market was down, my colleagues at Squawk on the Street, David Faber and Carl Quintanilla, were questioning me about whether we just turn to the same old same old growth stocks...
Amgen Inc. (NASDAQ:AMGN) Q3 2025 Earnings Call Transcript
Operator: My name is Julianne, and I will be your conference facilitator today for the Amgen Q3 2025 Earnings Conference Call.
Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study
On October 3, Oppenheimer reaffirmed its Outperform rating on Amgen Inc. (NASDAQ:AMGN) with a price target of $380.
Hedge Fund Resource Center Billionaire Hedge Funds
